Liquidia Corporation Strengthens Financial Position by Amending HealthCare Royalty Agreement to Incrementally Add Up to $100 Million

Core Insights - Liquidia Corporation has entered into a sixth amendment with HealthCare Royalty to secure up to an additional $100 million in financing for the development of its therapies, particularly YUTREPIA™ [1][2] - The funding will be utilized for the ongoing commercial development of YUTREPIA for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), as well as for other clinical trials and general corporate purposes [1][2] Financing Details - The agreement includes an initial$25 million at closing, with potential additional tranches of $50 million upon the first commercial sale of YUTREPIA after FDA approval, and$25 million upon reaching net sales exceeding $100 million by June 30, 2026 [2] - Payments to HealthCare Royalty are capped at 175$5 billion in more than 90 biopharmaceutical products [5]